What Matters to Patients
We know the industry is ready to embrace decentralized clinical trials. But what about patients? What do they think about decentralized clinical trials? What elements are important to them? And what should sponsors consider when designing such trials?
To dig deep, we spoke one-on-one with Phil Kelly, a bladder cancer patient and advocate. He shares his experience and insight in Part 1 of this series on the patient perspective. In Part 2, we delve further into the patient perspective on decentralized clinical trials. We ask Phil to share his thoughts on patient needs, tools, technologies, and the patient experience.
About Phil Kelly
Phil was diagnosed with bladder cancer almost 11 years ago, and after he completed his active treatment, he drew on the experience to help others. He is actively involved with one of the two bladder cancer charities in the UK, Action Bladder Cancer UK, initially as a trustee and more recently as a patient adviser. He has also been involved in providing one-on-one support for individual bladder cancer patients in different situations and at different stages of their treatment.